Myovant : FDA Identifies 'deficiencies' In SNDA Review Of Myfembree On Endometriosis-related Pain

Myovant Sciences (MYOV) and Pfizer (PFE), in an update on supplemental new drug application for myfembree for the management of moderate to severe pain associated with endometriosis, said the U.S. Food and Drug Administration identified deficiencies that preclude discussion of labeling and/or post-marketing requirements and commitments at this time.

The companies stated that the FDA did not provide additional detail. The FDA noted that the letter does not reflect a final decision on the pending sNDA and that the application is still under review.

The company said they will continue to work with the FDA to determine next steps with the application.

MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is the once-daily oral treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women approved by the U.S. Food and Drug Administration, with a treatment duration of up to 24 months.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT